2025-524974-41-00招募中2 期
J2S-MC-GZMT: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants with IBS-C
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 70
- 试验地点
- 25
- 主要终点
- Percentage of Participants with a Weekly Composite Clinical Response for at Least 50 Percent (%) of Weeks
研究概览
简要总结
To evaluate the efficacy of brenipatide relative to placebo in adult participants with IBS-C based on the weekly composite clinical response from Weeks 9 to 16
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Meets Rome IV criteria for irritable bowel syndrome-constipation (IBS-C) including having more than 25% bowel movements with Bristol Stool Form Scale (BSFS) Types 1 or 2 and less than 25% of bowel movements with BSFS Types 6 or 7
- •Based on the daily eDiary collection during the screening period: Have average of worst abdominal pain score of ≥3.0 on a 0-to-10-point scale during the 14 consecutive days prior to randomization
排除标准
- •Have a diagnosis of irritable bowel syndrome (IBS) with a subtype of diarrhea, mixed IBS, or unclassified IBS by the Rome IV criteria
- •Have a history of inflammatory or immune-mediated gastrointestinal disorders
- •Have a known clinically significant gastric emptying abnormality
研究组 & 干预措施
Placebo to match LY
Placebo
干预措施: Placebo to match LY (Drug)
Brenipatide, Brenipatide, Brenipatide
Test
干预措施: Brenipatide (Drug)
结局指标
主要结局
Percentage of Participants with a Weekly Composite Clinical Response for at Least 50 Percent (%) of Weeks
Percentage of Participants with a Weekly Composite Clinical Response for at Least 50 Percent (%) of Weeks
次要结局
未报告次要终点
研究者
Lilly Clinical Trials information desk
Scientific
Eli Lilly & Co.
研究点 (25)
Loading locations...
相似试验
尚未招募
Unknown
Actions and the Mechanisms of MaZiRenWan (MZRW) for Functional Constipation and Constipation-Predominant Irritable Bowel SyndromeChiCTR2100043211Health@InnoHK Initiative Fund of the Hong Kong Special Administrative Region Government (ITC RC/IHK/4/7)
招募中
2/3 期
Effects of Bacillus Clausii with IBS-Diarrhea patientsCTRI/2025/07/090307S K Biobiz Pvt Ltd46
进行中（未招募）
2 期
评估 Brenipatide 治疗腹泻型肠易激综合征的有效性和安全性研究腹泻型肠易激综合征CTR20261999Eli Lilly and Company/
礼来苏州制药有限公司/
Incog Biopharma Services,Inc.
招募中
3 期
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)2025-522313-38-00Eli Lilly & Co.47
尚未招募
不适用
IBS-Oriented CDED Versus Low FODMAP Diet for Irritable Bowel SyndromeIrritable Bowel Syndrome (IBS)NCT07707635Ariel University150